Technetium Tc-99m maraciclatide
Also known as: 99mTc-maraciclatide, 99mTc-NC100692, maraciclatide, NC100692, Tc-99m NC100692
Source Technetium Tc-99m maraciclatide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Maraciclatide is a cyclic RGD peptide labeled with technetium-99m, used experimentally for SPECT imaging of αvβ3 integrin expression in tumors and vascular disease.
Mechanism of Action
Binds αvβ3 integrin; radiolabeled with 99mTc for SPECT imaging of angiogenesis
Routes of Administration
Goals & Uses
- Lung cancer imagingDiagnostic OncologyLow
- Breast cancer lesion detectionDiagnostic OncologyModerate
- Assessment of anti-angiogenic therapy responseTheranostic MonitoringLow
- Cardiovascular disease assessmentDiagnosticLow
- Atherosclerotic plaque imagingCardiovascular DiagnosticsLow
- Imaging tumor angiogenesisDiagnostic OncologyModerate
- Tumor angiogenesis imagingDiagnosticModerate
Contraindications
- Severe renal impairmentOrganModerateKidney function concerns
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- Severe allergy to technetium or peptide componentsAllergicModerate
- Known hypersensitivity to RGD peptides or excipientsAllergyHigh
- BreastfeedingPopulationModeratePotential transfer into breast milk or insufficient safety data
Adverse Effects
- Radiation exposureRadiologicalUnknown
- Allergic reactionImmunologicRareImmune-mediated hypersensitivity response
- Injection site reactionsLocalUncommon
- Injection site painLocalCommonPain at the injection site
- Hypersensitivity/allergic reactionsImmunologicRare
- NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
Drug Interactions
- Other Tc-99m radiopharmaceuticalsModerate
- Anti-angiogenic agents (e.g., bevacizumab, sunitinib)Moderate
- Other radiopharmaceuticalsModerate
Population Constraints
- Pediatric patientsAgeRelative
- Breastfeeding womenReproductiveRelative
- Pregnant womenReproductiveAbsolute
- Patients with severe renal impairmentOrgan ImpairmentRelative
Regulatory Status
- European UnionUnapprovedNot authorized for clinical use
- United StatesInvestigationalInvestigational New Drug (IND) studies only
- United KingdomInvestigationalEvaluated in UK clinical trials including breast cancer SPECT studies; not approved for routine clinical use.
Investigated under IND/CTA in multiple jurisdictions. Phase II clinical trials conducted. Not currently FDA-approved or EMA-approved for routine clinical use as of the knowledge cutoff. Classified as an investigational radiopharmaceutical.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Technetium Tc-99m maraciclatide?
Maraciclatide is a cyclic RGD peptide labeled with technetium-99m, used experimentally for SPECT imaging of αvβ3 integrin expression in tumors and vascular disease.
What is Technetium Tc-99m maraciclatide used for?
Technetium Tc-99m maraciclatide is educationally associated with: Lung cancer imaging, Breast cancer lesion detection, Assessment of anti-angiogenic therapy response, Cardiovascular disease assessment, Atherosclerotic plaque imaging, Imaging tumor angiogenesis, Tumor angiogenesis imaging. Educational only — not medical advice.
How is Technetium Tc-99m maraciclatide administered?
Recorded routes of administration: Intravenous.
What are the potential side effects of Technetium Tc-99m maraciclatide?
Reported adverse effects include: Radiation exposure, Allergic reaction, Injection site reactions, Injection site pain, Hypersensitivity/allergic reactions, Nausea. This list is not exhaustive — consult a qualified clinician.
Who should avoid Technetium Tc-99m maraciclatide?
Recorded contraindications: Severe renal impairment, Pregnancy, Severe allergy to technetium or peptide components, Known hypersensitivity to RGD peptides or excipients, Breastfeeding. Consult a qualified clinician before use.